Literature DB >> 32696195

[Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020].

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32696195     DOI： 10.1007/s00347-020-01170-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  23 in total

1.  Reactivation of retinopathy of prematurity after bevacizumab injection.

Authors:  Jennifer Hu; Michael P Blair; Michael J Shapiro; Steven J Lichtenstein; John M Galasso; Rashmi Kapur
Journal:  Arch Ophthalmol       Date:  2012-08

2.  [Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  2005-05       Impact factor: 0.700

Review 3.  A systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine.

Authors:  Julie Aitken; Fiona L R Williams
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2013-10-08       Impact factor: 5.747

4.  Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.

Authors:  Chung-Ying Huang; Reyin Lien; Nan-Kai Wang; An-Ning Chao; Kuan-Jen Chen; Tun-Lu Chen; Yih-Shiou Hwang; Chi-Chun Lai; Wei-Chi Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-12-30       Impact factor: 3.117

5.  High myopia associated with retinopathy of prematurity is primarily lenticular.

Authors:  Enrique Garcia-Valenzuela; Lawrence M Kaufman
Journal:  J AAPOS       Date:  2005-04       Impact factor: 1.220

6.  Morphometric analysis of pars plana development in humans.

Authors:  R J Hairston; A M Maguire; S Vitale; W R Green
Journal:  Retina       Date:  1997       Impact factor: 4.256

7.  Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.

Authors:  Lingkun Kong; Amit R Bhatt; Ann B Demny; David K Coats; Alexa Li; Effie Z Rahman; O'Brian E Smith; Paul G Steinkuller
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-22       Impact factor: 4.799

8.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

Authors:  Megan M Geloneck; Alice Z Chuang; W Lloyd Clark; Michael G Hunt; Alan A Norman; Eric A Packwood; Khaled A Tawansy; Helen A Mintz-Hittner
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

9.  [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab].

Authors:  Monika Andrassi-Darida; Christine Mais; Knut Stieger; Birgit Lorenz
Journal:  Klin Monbl Augenheilkd       Date:  2019-11-26       Impact factor: 0.700

10.  Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Authors:  Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante Joseph Pieramici; Robert See; Stephen Couvillion; Ma'an A Nasir; Melvin D Rabena; Kha Le; Mauricio Maia; Jennifer E Visich
Journal:  Br J Ophthalmol       Date:  2014-07-07       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.